Associated Papers
TP53 germline pathogenic variants in modern humans were likely originated during recent human history.
Kou SH et al.
Nar Cancer, 2023
37304756 (PubMed )
Supplement: zcad025_supplemental_files.zip › Supplementary_Table_2.xlsx › BVs
Identification and functional characterization of new missense SNPs in the coding region of the TP53 gene.
Doffe F et al.
Cell Death and Differentiation, 2021
33257846 (PubMed )
Supplement: 41418_2020_672_MOESM1_ESM.pdf
Significant impact of circulating tumour DNA mutations on survival in metastatic breast cancer patients.
Muendlein A et al.
Scientific Reports, 2021
33762647 (PubMed )
Supplement: 41598_2021_86238_MOESM2_ESM.xlsx › Tabelle1
From uncertainty to pathogenicity: clinical and functional interrogation of a rare TP53 in-frame deletion.
Quinn EA et al.
Cold Spring Harbor Molecular Case Studies, 2019
30886117 (PubMed )
Supplement: supp_mcs.a003921_Supplemental_Table_1a.xlsx › S_Table1a._TP53_in_ClinVar
The genomic landscape of cutaneous SCC reveals drivers and a novel azathioprine associated mutational signature.
Inman GJ et al.
Nature Communications, 2018
30202019 (PubMed )
Supplement: 41467_2018_6027_MOESM14_ESM.xlsx › Sheet1
Recommended Guidelines for Validation, Quality Control, and Reporting of TP53 Variants in Clinical Practice.
Leroy B et al.
Cancer Research, 2017
Select a paper to view details